Prestige Consumer Healthcare Inc (PBH) 2015 Q4 法說會逐字稿

Good day, ladies and gentlemen, and welcome to the Q4 2015 Prestige Brands Holdings, Inc., earnings conference call.

My name in LeeAnn and I will be your operator for today.

(Operator Instructions) As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to Dean Siegal, Director of Investor Relations.

Please proceed.

Good morning and welcome.

As a reminder, there is a slide presentation which accompanies this call.

It can be accessed by visiting PrestigeBrands.com, click on the Investor link, and then on today's webcast and presentation.

I am required to remind you that during this call management may make forward-looking statements regarding their beliefs and expectations as to the Company's future business prospects and results.

All forward-looking statements involve risks and uncertainties which in many cases are beyond the control of the Company and may cause actual results to differ materially from management's expectations.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this conference call.

A complete Safe Harbor disclosure appears on page 2 of the presentation accompanying the call.

Additional information concerning the factors that might cause actual results to differ from management's expectations is contained in the Company's annual and quarterly reports which it files with the US Securities and Exchange Commission.

Now I would like to introduce Matt Mannelly, CEO, and Ron Lombardi, CFO.

Good morning.

Thank you, Dean.

Thank you, everyone, for joining us this morning.

We appreciate it.

As Dean said, as we usually do, we will be operating off a PowerPoint presentation, so with that I will ask you to move to slide 3. The agenda for today will be I will talk about the fourth-quarter FY15 highlights.

I will also step back and talk a little bit about the year since this is the year-end.

Ron then will step in and give you a little more detail on the financial overview, as well as take you through the FY16 outlook and the road ahead, which is appropriate given the transition.

So with that I will ask you to turn to slide 5. I think, for us, obviously we are very pleased with the fourth-quarter results.

I think, as importantly, we are very excited about the business fundamentals and how we achieved those results, which we will talk a little bit about.

But our Q4 revenue of $190 million is up almost 33% versus the prior year.

Our organic growth on a constant currency basis is up 2.4%, which is the second quarter in a row we have come in very strong.

Our core OTC consumption growth, excluding PediaCare, is up 7% and total core OTC is up 3.3%.

And as importantly, which I will talk about a little bit later on, we have really seen broad-based growth across the entire core OTC portfolio.

In addition, we continue to make progress on the gross margin front and you can see that we are up almost 3 points versus the gross margin last year's fourth quarter and we are also up 0.7 points versus the third quarter, which we are quite pleased with.

In terms of earnings per share, $0.47 is up over 34% versus the prior year and I think the statistic that we always talk about that is just really critical to our success and our foundation is our free cash flow.

And our adjusted free cash flow of over $50 million is up 45% versus the fourth quarter last year.

And that takes our leverage down to 5.2, which is already down half a turn since the acquisition six months ago.

So, again, that continues to be critical to our success and that strong cash flow continues to be important to us.

In terms of kind of a little bit of a why, we have consistently, in good times and bad, spent money behind marketing to support brand-building programs and it has achieved results for us.

A couple examples.

Clear Eyes, for the very first time this quarter, achieved number one market share in the redness segment, which is huge for us.

A solid cough/cold season coming off a very poor one the year before.

Not only a solid cough/cold season, but you can see Chloraseptic and Luden's gained over 4 share points.

And that was driven primarily to digital marketing, where we've been spending more and more money and we are obviously getting the bang for the buck.

Finally, Little Remedies continues to have very strong consumption gains across all segments and that is as a result of really an integrated program in terms of TV and digital marketing support.

So with that, if you turn to slide 6, like I said I would like to step back and take a moment and just take a look at the total year FY15 in review.

And on slide 7 I think what I would say is FY15 was a year of great execution for us in terms of focusing on the value creation drivers that contribute to our success.

First and foremost, and I will talk about each of these a little bit more, organic growth in our core OTC and international, we continue to put focus behind it.

It continues to yield dividends for us.

I'm also going to talk about the fact that our portfolio -- if you look at how our portfolio has morphed over time and the results it's achieving, we are really doing exactly what we said we were going to do.

Third, from a margin standpoint, we continue to gain gross margin.

Again, as we have said throughout, our bottom-line EBITDA margin is terrific.

We want to take that gross margin expansion and continue to reinvest it in the business, and we've been doing that with some success.

Fourth is our free cash flow, which has been very consistent, and as I said, increasing over $50 million this quarter.

And then finally, if you step back and look at all of FY15, again our proven and repeatable M&A strategy with two acquisitions this year certainly contributed to our success.

But if you look at those things in terms of first how they contributed to FY15's success, the second thing to note is they also put us in a very strong position for FY16 and beyond.

With that if you turn to slide 8 to go through a little bit in terms of our growth trends.

The top part is consumption, consumer takeaway; the bottom part of the chart is shipments.

And you can see on the left-hand side is FY12, FY13, and FY14.

You can see FY15 was a very strong year for both consumption growth and shipment growth.

And as importantly, you can see on the right-hand side of the chart it shows what happened by quarter and how our growth has accelerated, both in terms of consumption and shipments throughout the year.

And the third and fourth quarter have been extremely strong for us.

With that, if you will turn to slide 9, and I referenced this earlier, the fact that our core OTC growth has been very broad-based and it's really been led by some of our largest brands.

So we got growth across the portfolio and 84% of our OTC portfolio had consumption growth in FY15, which we are very pleased with.

On the right-hand side, if you look at some of our largest brands, you can see how well they are doing from a year-over-year sales growth number.

In addition, you can see how those numbers are increasing as the year has gone on.

So as I said, the fundamentals are very strong as we head into FY16.

Slide 10, again I referenced this earlier about achieving the desired results.

I think it's important; if you step back to a few years ago, we talked about our core OTC portfolio represented 66% of our revenue.

So our core OTC portfolio and our international business now represents 78% of our portfolio.

That is a significant change over the last few years and that's really the part of the portfolio we are now investing in for growth for the future.

And you can see FY15 at organic growth, excluding PediaCare, was plus 2.9% in the investment area and nearly flat in the managed for cash area, leading to 2% organic growth for the full fiscal year, excluding PediaCare.

Turning to slide 11.

Again, in terms of how we're supporting the business, that margin expansion is really helping us.

Our margin expansion and our G&A synergies with our acquisitions is what is helping us increase our A&P.

And if you look at just five years ago, where we spent less than $40 million, this year we are spending about $100 million in A&P.

And we believe that's the right thing to do in terms of building brand equity for the long term.

Slide 12 gives a couple of examples of areas that we are focusing on in terms of our marketing spend.

I think the first that we've talked about quite a bit is we really believe that the pipeline for new products and what we have done the last couple years that we're just getting started.

And if you look at some of the latest introductions, Dramamine Naturals was just introduced and we are seeing strong success already.

You can see Compound W we had a new introduction that came in the fourth quarter, as well as some things with Fiber Choice, Goody's, and Little Remedies.

So this is an area that we have brought focus to over the last couple years.

We had success in FY15 as a result of it, and more importantly, we really are well positioned for FY16 and FY17 with regards to new and innovative products.

In terms of marketing support in the marketplace, we have had terrific success in terms of this year in-store merchandising, on Luden's specifically, which has led to terrific growth; off-shelf merchandising.

And we've also had terrific success in terms of leveraging our sports marketing assets, specifically Dale Earnhardt Jr., to get us merchandising in stores that has led to continued success with for Goody's as well.

Then, finally, we have talked about in previous calls about expanding our marketing toolkit and no longer being a company that really is one-dimensional, but doing things from a marketing -- from a TV, from a sports marketing, from a digital marketing standpoint.

And we continue to do that and expand that toolkit across all of our key brands.

Slide 13 is Little Remedies and Little Remedies had a terrific year, and we believe Little Remedies differentiation really positions it well for long-term success.

Little Remedies will be our lead pediatric brand moving forward because of that differentiation in the marketplace versus the competitive brands.

And you can see the growth that new products has helped deliver for Little Remedies, as well as we have done quite a bit of digital advertising around Little Remedies for really the last five years.

You can see the consumption trend, latest 20-week of plus almost 4% and latest 12-week consumption trends for Little Remedies up nearly 9%.

So we are quite pleased with the momentum of Little Remedies.

We're also quite pleased in the competitive environment how Little Remedies point of difference and differentiation versus the competition is resonating so strong with the consumers.

Slide 14, we talked about this on the last call.

We really have spent a lot of time and money, candidly, in FY15 in terms of learning about our fem hygiene platform that we bought six months ago.

And we really believe that learning is going to position us quite well for our first $100 million brand.

Specifically, we have a new ad campaign -- TV ad campaign the kicks off this quarter and I think the consumer insights that we found that will really be important as we move forward are Monistat's prescription strength cure without a prescription, so you can get it really on demand.

And the second thing that resonates with consumer is the relief starts curing right on contact.

So those are going to be some of the key messages that we will be getting out there.

And as we've said, we also have kicked off -- and were just at ACOG, which is one of the major trade shows for the healthcare industry -- two weeks ago.

We are developing very strong relationships with healthcare professional community, employing a salesforce, and doing quite a bit with that group that we intend to commit to for the long term, and we believe will really be pivotal to our long-term success for Monistat.

Turning to slide 15, as I said previously again, cash flow is really critical to our success.

If you look in the upper right-hand corner, we really delivered significantly more free cash flow this year than we gave guidance to at the start of the year, and we ended up with $164 million in free cash flow in FY15.

That exceptional free cash flow has allowed us to pay down debt and in a significant way.

And you can see here, which we do for similar type acquisitions in the future that we have done in the past, we would have approximately $1.5 billion of traditional debt capacity available by the end of this year.

To put it in perspective, that $1.5 billion is the aggregate amount -- more than the aggregate amount of our two largest acquisitions.

So we are building significant capacity for M&A.

Slide 16 talks a little bit about M&A in terms of this has really been critical to our success.

I think -- and I keep using the word -- it's proven and it's repeatable, and we are doing it in a very favorable M&A environment that continues to be very favorable, as you can see with what is going on over the last few weeks in the OTC and the healthcare business.

As I said, we completed six acquisitions in last five years for total enterprise value of about $2 billion.

And as Ron will talk about at the end, we will continue to be aggressive and disciplined in our M&A strategy moving forward.

If you turn to slide 17, I like this slide and really the next slide because it helps really put in perspective how our portfolio has morphed over the last five years.

So you can see the first slide on 17 say what were our key brands and the key category platforms which we participated in back five years ago.

And you can see the brands in there.

If you turn to slide 18, you can really see how that has changed dramatically.

And I think the conclusions are, number one, we are building a great portfolio.

Second of all, it really talks to the power of the portfolio, so I will give you a couple examples.

Clear Eyes, we have had great success with Clear Eyes in the C-store channel this year in particular, because of our portfolio and the strength of BC and Goody's in that C-store portfolio.

The second example is, as we have said, PediaCare, with the return of the competing brands, has had a rough year, but the thing to note is, given the power and size of our portfolio, no one brand can drive our portfolio success over the course of the year.

It's really the power of the entire portfolio that determines our success, so we're excited about that.

Slide 19, I think the strategy has clearly delivered strong financial performance.

You can see our sales CAGR of about 20% per year.

Our EPS and free cash flow CAGR of about 23% per year over the last four to five years we are very proud of and believe we can continue to deliver the results over the long term.

So with that, I will turn it over to Ron.

Thanks, Matt, and good morning, everyone.

So let's begin on slide 21.

We will look at some of the highlights for the fourth quarter.

As Matt described, we are really very pleased with our fourth-quarter and full-year results, including our record revenues for both periods, and the very strong organic growth of about 2.5% for the fourth quarter.

This quarter continued our trends of strong organic sales growth across our core OTC brands and international portfolios.

This resulted in extremely strong fourth-quarter and full-year results.

Our results for the quarter included not only solid revenue and EPS growth, but excellent strong free cash flow generation and the strengthening of our overall financial profile.

If you look down at the bottom of page 21 you will see that total revenue grew about 33% during the quarter to $190 million, a record for the fourth quarter.

Our adjusted EPS growth was ahead of the sales growth at about 34% to $0.47 for adjusted EPS.

And then, finally, that excellent free cash flow growth of about 45% to just over $50 million during the quarter.

So again we are very pleased with the results during the quarter.

Turning to slide 22, we have our consolidated fourth-quarter and full-year results.

As a reminder, today's information includes adjusted results that are reconciled in our earnings release.

Our net revenues increased again about 33% in Q4 and about 20% for the full year with full-year sales coming in at approximately $715 million.

These results were driven by continued strengthening consumption trends across our core OTC brands as well as in our international portfolios.

These results include about $2 million of negative FX impact in Q4 and about $4 million on a year-to-date basis.

We expect currency fluctuations to impact our business approximately $10 million in fiscal 2016 based on current FX value for the Australian and Canadian dollars.

Our fourth-quarter gross margin was just about 58% compared to 55% a year ago, and this quarter was the highest level in the past six quarters and was largely in line with what we expected.

We anticipate continued improvements in gross margin in fiscal 2016 and expect to be at about 58% for the full year next year.

In terms of A&P, we came in at just over 13% of sales for the fourth quarter and just about 14% for the full year, with significant dollar increases over the prior-year period.

We expect fiscal 2016 A&P levels to continue to increase above 2015 with gross margin gains being invested in higher-level A&P levels, as Matt described earlier.

Adjusted G&A came in at about 8.5% of revenues in the fourth quarter and about 8% for the full year, and again was in line with what we expected.

G&A for fiscal 2016 should be in the 8% of sales range.

Finally, our adjusted EPS for both periods continues to grow faster than revenues as a result of operating leverage and margin gains.

Fourth-quarter EPS growth was approximately 34% and full-year EPS growth was about 22%, which were both well above revenue gains.

Turning to slide 23, we have the details to our cash flow for the quarter and the year.

We experienced extremely strong adjusted free cash flow growth of approximately 45% for the quarter, while continuing to strengthen our financial profile and pay down debt.

We generated just over $50 million of adjusted free cash flow during the quarter and $164 million for the full year.

Our excellent cash flow continues to be generated from our industry-leading strong and consistent EBITDA levels, low fixed asset additions, and a meaningful deferred tax asset benefit.

We are able to reduce our net debt again by about $50 million during the quarter, and as Matt mentioned earlier, we reduced our leverage ratio to approximately 5.25 times, which was a full 0.5 point reduction from where we were just six months ago right after the Insight acquisition.

We forecast further reductions in the leverage ratio to approximately 4.4 times by the end of fiscal 2016.

This leverage reduction is expected to create over $1.5 billion of M&A capacity and will continue to support our M&A objectives going forward.

Turning to slide 26 -- excuse me, slide 25, we will take a look at the FY16 outlook and the road ahead.

Brand building has been at the center of our value creation over the last five years and will continue to be going forward.

We have executed against our three-pronged strategy, which has delivered significant results over the last five years and the power of our portfolio has us well-positioned moving into fiscal 2016.

Brand building and a focus on new product development and innovation will continue to be key focuses in fiscal 2016.

And as Matt described earlier, our Little Remedies brand and its point of difference will be the center of our pediatric efforts going forward.

In terms of Insight, fiscal 2016 will be an investment year for the Insight portfolio.

Our investments will be targeted at the healthcare professionals and new advertising for Monistat, and both will launch in the first quarter.

We will also prioritize the development of new product pipelines for our women's healthcare platform to support long-term growth objectives.

M&A has been an important part of our strategy and aggressive and disciplined M&A will continue to be a focus going forward.

Our consistent and industry-leading cash flow has us rapidly delevering and is creating meaningful M&A capacity to support it.

Industry dynamics and big pharma portfolio rationalization is expected to continue and we are well positioned to address opportunities as they arise going forward.

Finally, for our FY16 outlook, we head into the year with strong momentum in our core OTC brands and our international businesses.

Consumer confidence is improving and retailers are cautiously optimistic, while remaining bottom-line focused.

Our specific outlook for fiscal 2016 has revenue growth of 10% to 12%, again including the impact of approximately $10 million of FX due to the lower Canadian and Australian dollar rates.

We expect full-year organic growth to be between 2% and 3% with first-half revenue expected to be at plus 20% to 23% over last year, largely due to the timing of last year's acquisitions.

Finally, second-half growth is expected to be at 1.5% to 2%.

Our adjusted EPS is expected to be ahead of revenue growth at 10% to 13% with continued A&P investments, especially behind the Insight brands.

Our excellent free cash flow is expected to grow approximately 7% and we expect to generate $175 million or more of free cash flow for the year.

Turning to slide 26, we will wrap things up with a few comments on our strategy and key drivers of long-term value before we open things up for questions.

Our strategy is in place and proven and we will continue to focus on brand building and growing our core OTC brands and international portfolio.

We have grown this portion of our business, as Matt mentioned earlier, from 67% of sales to 78% of sales over the last five years and we look to grow to a target of 85% over time.

We like our asset-light business model.

Its proven ability to grow and flex with the business and the industry-leading financial profile that it helps create for us.

Our strong and consistent free cash flow will continue to rapidly delever and build M&A capacity.

And, finally, we will remain aggressive and disciplined in M&A and feel well-positioned to capitalize on the industry dynamics and opportunities going forward.

So with that, why don't we open up the call for questions for Matt and I?

(Operator Instructions) Joe Altobello, Raymond James.

Thank you.

Good morning, guys.

First question wanted to talk about PediaCare a bit.

It sounds like you guys are starting to deemphasize that brand somewhat.

I imagine that has to do with some of the competition you are seeing from Children's Tylenol.

So I guess, first, can you talk about that change in your strategy?

Second, maybe what you are seeing in terms of the overall spending level for that brand and from competition?

Yes, Joe, I will be happy to talk about that.

If you go back to the conference calls over the last two years, we said we are really going to look at this over two seasons and see how things settle out.

And so with the end of this cough/cold season as we enter 2016 with our annual operating plan, the analysis and the strategies that we developed, we said we're still very bullish on the pediatrics market.

We just believe Little Remedies is more differentiated than PediaCare vis-a-vis the competition, so that's where we will be investing more A&P dollars.

And as we have done in the past with our portfolio, we have to make choices in our A&P spending.

So we're going to pull back the A&P spending a little bit in PediaCare; we're going to put it behind Little Remedies because it's more differentiated.

We're still going to support PediaCare.

We have some exciting things with PediaCare in terms of target audiences, some things we do with the Hispanic community with PediaCare.

We also have some exciting things that we are looking at in terms of channels of distribution and better leveraging PediaCare in the dollar channel.

So we are going to shift strategies.

We're going to deemphasize it a little bit.

As I said earlier, one, we said we were going to assess after two years.

And, two, I think what you saw this year, the power of the portfolio was even though that competitive onslaught and the marketing spend continued into the second half, we still saw terrific overall growth for the Company in the OTC portfolio.

Does that answer your question, Joe?

It does, thank you.

Secondly, on Monistat (multiple speakers).

Joe, just to add two comments to that, if you take a look at our total organic consumption trends in Q3 and Q4 in the heart of the cough/cold season, to Matt's point, you will see that we were able to still have very nice performance during that period.

Right, right, okay.

And then in terms of moving to Monistat, that brand has started to grow with you guys owning it even before the direct marketing to the OB/GYN.

So what is driving that and how much upside do you see for that brand in the next year?

I think what has driven it to date, Joe, is some basic blocking and tackling that we did when we bought the business in terms of aligning the correct pricing across the portfolio in some of our key customers.

So little things like that make a difference to the portfolio.

And I think over time, and I think it's over the next couple years, we see terrific opportunities and upside for Monistat.

That's why we're going to be investing significantly in it.

I would note, though, the healthcare professional play is a long-term play.

That is not something we're doing to drive revenue in 2016.

We're really doing it to drive it in 2017 and 2018 even more.

Got it.

Thank you, Matt.

Carla Casella, JPMorgan.

My question was related to the additional ad and promo spend.

Did you give a magnitude of how much additional spend?

And if we look specifically at second quarter when you are spending behind the Monistat spending in the professional trade, how should we look at the second-quarter spend versus last year?

Carla, we really don't break out expectations on a quarter-by-quarter basis.

We do see some fluctuations between quarters, but our focus and our investment for the entire year of fiscal 2016 will be significant, especially behind the Monistat brands and initiatives we've got going on for healthcare, professional, and updating our advertising and TV commercials that we expect to do.

Okay.

I guess I was more just wondering is it --?

Are you moving the dollars around in this coming quarter, I guess first fiscal quarter?

Or will we see more of the ad and promo be weighted towards this first quarter than it was in the past?

We will see increases in the first half of the year, Carla, between those -- the first and second quarter year over year as we begin to get investments behind the Monistat and some of the other initiatives we've got going on.

Okay, great.

Thank you.

Jon Andersen, William Blair.

Good morning, everybody.

The first question I had is just more on the fourth quarter.

The top-line number was stronger than -- quite a bit stronger than the guidance.

I think for the guidance for the year we were looking for like 18% and came in closer to 19.5%, which had a --.

And that was driven by Q4 results.

So what -- just curious what came in stronger, if you can parse that out?

Was it a particular brand or collection of brands?

Was it the international business?

Was it the strength of the cough/cold season?

Any help there would be great.

Sure.

First thing I will mention, Jon, is that the cough/cold season, the incident levels trended all the way up through the end of the fourth quarter, which were a bit above what we expected going into the fourth quarter.

That's always a tough call.

Another thing I will call out is the continued strong performance of Clear Eyes.

As Matt mentioned earlier, we took -- became the number one brand in the redness category and then overall continued strong trends in our core OTC brands in our international portfolio.

I think it's the consistent A&P spending we have been putting behind the business.

As I said, we yielded broad-based consumption gains across the core OTC, which we are really happy about.

Okay, that makes sense.

I guess sticking with advertising and promotion, Ron, I think in the prepared comments you mentioned that you expect A&P in 2016 to be above the 2015 level.

Just for clarification purposes, do you mean above on an absolute level or on a rate basis as a percent of sales, or both perhaps?

Both.

We expect to take gross margin gains and invest them in higher levels of A&P, which will result in both a percent and dollar increase year over year.

Okay, that's helpful.

The gross margin rate of 58%, kind of the run rate level, is -- obviously that's a terrific gross margin rate.

Is that the right way --?

I guess you will have a full year of impact from Insight next year.

Is that a level which we should think of as a run rate level for a longer period of time, or I guess are there other internal initiatives and/or I guess future M&A that could even move that higher over time?

Yes, for 2016, as I mentioned earlier, we expect to be at approximately 58% so the fourth-quarter run rate will be where we start to get into for fiscal 2016.

And then I think we've mentioned this in the past; we've got midterm objectives of growing our gross margin closer to 60% over time.

We've got cost-saving initiatives that we will execute against over time.

And certainly as we grow our OTC business and it becomes a larger portion of our total sales and household continues to become a smaller portion, we will get a benefit of mix.

Again, it's our intention to take those increasing margins and invest them in higher levels of A&P going forward.

Okay, just a couple of quick housecleaning questions.

The G&A spend in the quarter was -- I think you've had Insight for the full quarter in third quarter, so the step up from $14 million to $16 million on the G&A line was a bit more than we had modeled.

Was there simply some year-end kind of true-up activity there?

How should we think about that for 2016?

We tend to have slightly higher G&A in the fourth quarter versus other quarters in the year.

Then the other thing that gets classified in G&A is we did have some FX losses during the quarter that get recorded in G&A, so that was a small amount of the increase over 8% as well.

Perfect.

Last question, the D&A and CapEx for 2016, I know CapEx is generally modest, but if you can help us with that it would be great.

Sure.

For D&A we were just under $6 million in the fourth quarter, so if you annualize that out we would expect around a $24 million number for next year.

And then D&A, we spent $6 million this year.

You could use that as an estimate for 2016 as well.

Okay.

Thanks, guys.

Frank Camma, Sidoti.

Good morning, guys.

I was wondering if you could just talk briefly about the inventory levels at retail.

You mentioned -- it sounds like the retailers, from your perspective, are becoming a little more optimistic so I was wondering if you could just address that.

I don't think -- we've talked about this in other quarters, Frank.

Third quarter and now fourth quarter, we are not seeing the broad-based pressure on inventories that we saw for several quarters.

It doesn't mean we are not seeing some inventory pressure from individuals, like the key accounts, because you still see a little bit of that.

But I think in general -- also when you look at our consumption trends versus our shipment trends over the last few quarters, our retail inventory is in good shape.

So I think Ron used the term retailers are cautiously optimistic, but they are still bottom-line-focused as we head into 2016.

So they are not going to take their eye off it.

We're not seeing the squeezing we saw 12 months ago on a broad-based level, but clearly, like I said, that is why the words are cautiously optimistic.

The retailers continue to look at that, but we don't see significant headwinds right now.

And we haven't benefited from any recovery in inventory at retail yet.

We are seeing a narrowing of consumption to shipments.

Okay, understood.

The other question just is on, I know it's obviously a smaller component, but household cleaning for about a year had actually seen some not only stabilization but growth in this quarter.

It actually came in at my expectation.

But was there anything driving that in this quarter, the slight decline here?

Frank, household -- some of that is dependent on programs and program is by channel and key customer, so there's always some movement around in terms of throughout the year.

So I don't think there's any fundamental change, it's just a shift in programs quarter to quarter.

Okay, thanks.

All right, thanks, that's all I have for now.

Linda Bolton Weiser, B. Riley.

I was curious just on PediaCare, as you deemphasize that, have you already lost any distribution or do you expect to in the future?

And how does the distribution of PediaCare compare with Little Remedies?

For example, is PediaCare in Walmart but Little Remedies isn't.

Are there any retailers that you can lose or actually with Little Remedies is there opportunity for distribution gain as you put more behind it?

Thanks.

Linda, for us, and it's similar for some other brands as well, but for Little Remedies and PediaCare we have distribution for both those brands in really all the major accounts.

Our distribution losses and our distribution opportunities are by SKU, not really for the brand.

This is why we believe Little Remedies has more upside because of its point of difference in terms of to grow and to gain distribution.

And to answer your question, PediaCare did take some distribution and facing losses this year already, so that has already happened.

Okay.

And are there any margin differences between the two brands in terms of the SKUs that are offered in each line or is it very similar in terms of the margin profile?

Very similar margins across those.

I mean, they are similar -- they're liquid products so very similar margins.

Okay.

And then I was curious about your guidance on organic sales for the year.

For FY16 it's quite robust at 2% to 3%, but you said I think for the second half it would be a little lower at 1.5% to 2%.

So is that a matter of just the comparisons that are harder in the second half, or is it launch schedule and what you have planned or the advertising cadence?

What is it that is making it sort of lower in the second half of the year?

It's really the comps, Linda.

We have very strong Q3 and Q4 results, as well as a fairly robust cough/cold incident level this year.

Okay.

And just finally, kind of the longer-term front, I know a lot of some of the larger household and personal care companies like Procter & Gamble are commenting on as they spend more on digital, you are actually seeing reductions in the advertising and promo ratio over time is what they are saying to expect.

It doesn't sound like you're really thinking that way, even though you are spending more on digital.

But can you just comment on that as a longer-term trend phenomenon?

I think for us, given our spend levels, where we were and where we are today, we are not looking to gain more efficiencies in A&P.

But we are not moving to digital to gain more efficiencies; we're moving to digital to gain more effectiveness with our consumers.

So we are not looking here to internally squeeze the A&P to cut it back.

We are looking where can we invest in A&P.

So I don't think for us we are seeing that that number is going to come down over the next couple years as a result of the move to digital.

Okay, great.

Thank you very much.

Kevin Ziets, Citi.

Good morning, thanks for taking my question.

It's more of a bigger picture question on I guess celebrity attachment to your products.

It seems like Clear Eyes and Goody's are examples where you have that and it has really worked.

And I don't expect you to say necessarily on a specific brand basis, but if you could just comment in general whether those types of products where you attach a celebrity to the marketing campaign, whether they have better growth in general and better margins all-in than maybe some of the other brands and whether you would think about doing that with some of your newer brands, maybe Monistat or something else.

Kevin, I think it's a good question.

I think -- again, what I tried to say earlier was look at our marketing mix portfolio in our toolkit and how it has changed over the last five years.

We used to be basically turn on the TV and drop a couple coupons.

Today we are much, much more than that.

Whether it's celebrities that we are using for different brands, whether it's sports marketing events, whether it's digital, blogging, etc., but I think we are going to continue to expand our toolkit.

I think that is what marketers do and I think we look at for all our different brands what are the assets that make sense, whether it celebrity or other things.

But we're going to continue to do that and we will probably continue to expand it.

And the beauty is in this industry gross margins are healthy enough that if you do it the right way you can afford to do that successfully.

That's great.

Thank you very much.

Thank you.

I would now like to turn the call back over to Matthew Mannelly for closing remarks.

Okay.

Thanks, everybody.

Just a couple closing remarks as we transition to Ron, given that this will be my last call.

I think, as trite as it sounds, it's about the people and I'll start with the passionate team members at Prestige that have built this company and will continue to build it.

It's also about the people on the call, the analysts who really have discovered us and written about us and our story along the way.

I can tell you, whether it's the conferences or really the market trips that we've spent with Joe Altobello, John San Marco, Frank Camma, Jon Andersen, and Linda Bolton Weiser, how enjoyable it has been and how much we respect the work that you have done and the investments that you have made in Prestige.

So we thank you for that.

Finally, it's about the investors as well.

We do a lot of meetings, a lot of one-on-ones with investors, and I don't mean to exclude anyone here.

But a couple of examples are I can tell you it's enjoyable to go up to Boston every couple of quarters and sit in one of the big Fidelity conference rooms and it's like a firing line of about 10 people asking you questions.

And that is a fun part of the business.

It's also enjoyable to deal with people like the people at First Manhattan, who have been with us the entire ride and continue to believe in us.

And it's enjoyable to deal with people like Black Rock who has built up their position considerably in the last couple years.

So that part of the business is an enjoyable part of it and I will just go back to the Prestige people.

Our culture is really built on leadership and we talk about it a lot here and the fact that we have 200 leaders in the Company.

What that does is it allows us that when one leaves we have plenty of other leaders to take us to the next level.

So I would like to thank the 200 leaders for what they have done and, more importantly, for what they're going to continue to do for Prestige.

So thank you for that.

With that, we will end the call and we appreciate everyone's time.

Have a good day.

Thank you.

Thank you for your participation in today's conference.

That does conclude the presentation and you may now disconnect.

Have a great day.